|
US7655699B1
(en)
|
1992-04-22 |
2010-02-02 |
Eisai Inc. |
Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
|
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
|
EP0738268B1
(en)
*
|
1993-12-22 |
2004-03-03 |
Celltech R&D Limited |
Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
|
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
|
US6942980B1
(en)
*
|
1995-09-01 |
2005-09-13 |
Allergan, Inc. |
Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
|
|
US5958954A
(en)
*
|
1995-09-01 |
1999-09-28 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
GB9523675D0
(en)
*
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9526243D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US5877207A
(en)
*
|
1996-03-11 |
1999-03-02 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
CN1255396C
(zh)
*
|
1996-03-18 |
2006-05-10 |
卫材株式会社 |
含有稠环的羧酸衍生物
|
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6555690B2
(en)
|
1996-06-21 |
2003-04-29 |
Allergan, Inc. |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
US5773594A
(en)
|
1996-06-21 |
1998-06-30 |
Allergan |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
JP2000511558A
(ja)
*
|
1996-06-21 |
2000-09-05 |
アラーガン・セイルズ・インコーポレイテッド |
レチノイドおよび／またはレチノイド拮抗剤様生物学的活性を有する置換テトラヒドロナフタレンおよびジヒドロナフタレン誘導体
|
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
EP0946523A1
(en)
*
|
1996-12-23 |
1999-10-06 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
|
US5760276A
(en)
*
|
1997-03-06 |
1998-06-02 |
Allergan |
Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
|
|
AU6955898A
(en)
|
1997-04-11 |
1998-11-11 |
Bristol-Myers Squibb Company |
Retinoid antagonists and uses thereof
|
|
EP1030662B1
(en)
*
|
1997-11-12 |
2006-08-02 |
F. Hoffmann-La Roche Ag |
Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
|
|
WO2000018885A1
(en)
*
|
1998-09-29 |
2000-04-06 |
Gamida Cell Ltd. |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
|
US6048873A
(en)
*
|
1998-10-01 |
2000-04-11 |
Allergan Sales, Inc. |
Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
|
|
US6147224A
(en)
*
|
1998-10-01 |
2000-11-14 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
US6403638B1
(en)
|
1998-10-01 |
2002-06-11 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
AU757448B2
(en)
*
|
1998-10-08 |
2003-02-20 |
Allergan, Inc. |
Male anti-fertility agents
|
|
US6521641B1
(en)
|
1998-10-08 |
2003-02-18 |
Allergan, Inc. |
Male anti-fertility agents
|
|
JP2002528721A
(ja)
*
|
1998-10-23 |
2002-09-03 |
グラクソ グループ リミテッド |
核内受容体のリガンド用のアッセイ
|
|
US6326397B1
(en)
|
1998-11-10 |
2001-12-04 |
Hoffman-La Roche Inc. |
Retinoid antagonists and use thereof
|
|
US6054623A
(en)
*
|
1998-12-18 |
2000-04-25 |
Alliedsignal Inc. |
Hydroxythiol grignard reaction synthesis
|
|
AU762492B2
(en)
*
|
1999-03-08 |
2003-06-26 |
Basilea Pharmaceutica Ag |
Retinoid antagonists and use thereof
|
|
AU4225500A
(en)
*
|
1999-04-14 |
2000-11-14 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease
|
|
AU4228000A
(en)
|
1999-04-14 |
2000-11-14 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease
|
|
ATE365158T1
(de)
|
1999-04-28 |
2007-07-15 |
Inst Med Molecular Design Inc |
Pyrimidincarbonsäurederivate
|
|
US6906057B1
(en)
|
1999-06-11 |
2005-06-14 |
Allergan, Inc. |
Methods for modulating FXR receptor activity
|
|
HK1047752A1
(zh)
|
1999-06-11 |
2003-03-07 |
Allergan, Inc. |
具有核激素受体调节活性的有机硅化合物
|
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
|
KR20020038741A
(ko)
|
1999-08-27 |
2002-05-23 |
윌리암 엘. 레스페스 |
안드로겐 수용체 조절 화합물 및 방법
|
|
JP2003508397A
(ja)
|
1999-08-27 |
2003-03-04 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
アンドロゲンレセプターモジュレーターとしての８−置換−６−トリフルオロメチル−９−ピリド［３，２−ｇ］キノリン化合物
|
|
AU7586600A
(en)
*
|
1999-09-14 |
2001-04-17 |
Ligand Pharmaceuticals Incorporated |
Rxr modulators with improved pharmacologic profile
|
|
US20030114482A1
(en)
*
|
1999-12-15 |
2003-06-19 |
Maurizio Pacifici |
Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
|
|
US6313168B1
(en)
*
|
1999-12-15 |
2001-11-06 |
Allergan Sales, Inc. |
Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
|
|
US6713515B2
(en)
|
2000-09-13 |
2004-03-30 |
Bristol Myers Squibb Company |
Retinoic acid receptor antagonists as promoters of angiogenesis
|
|
US20030003517A1
(en)
*
|
2001-03-22 |
2003-01-02 |
Klein Elliott S. |
Methods of detecting dissociated nuclear hormone receptor ligands
|
|
US20020193403A1
(en)
|
2001-05-03 |
2002-12-19 |
Allergan Sales, Inc. |
Methods of treating hyperlipidemia
|
|
BR0209774A
(pt)
|
2001-05-29 |
2004-06-01 |
Schering Ag |
Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
EP1465869B1
(en)
|
2001-12-21 |
2013-05-15 |
Exelixis Patent Company LLC |
Modulators of lxr
|
|
IL152904A0
(en)
*
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
|
WO2003062404A1
(en)
|
2002-01-25 |
2003-07-31 |
Gamida-Cell Ltd. |
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
|
|
CN101348763B
(zh)
*
|
2002-06-20 |
2012-07-18 |
普里梅拉蒂斯有限公司 |
用于多聚核苷酸检测和定量的设备
|
|
WO2004014388A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Warner-Lambert Company Llc |
6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
|
|
US7105566B2
(en)
*
|
2002-10-22 |
2006-09-12 |
Allergan, Inc. |
Methods of treatment during vascular procedures
|
|
FR2847255B1
(fr)
*
|
2002-11-18 |
2006-11-17 |
Galderma Res & Dev |
Nouveaux ligands antagonistes des recepteurs rars, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
|
ES2283866T3
(es)
|
2002-11-18 |
2007-11-01 |
GALDERMA RESEARCH & DEVELOPMENT |
Nuevos ligandos que son antagonistas de los receptores rar, procedimiento de preparacion de estos ligandos y utilizacion de estos ligandos en el campo de la medicina humana y de la cosmetica.
|
|
US20050026950A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
|
|
AU2004261286A1
(en)
*
|
2003-07-30 |
2005-02-10 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoid components
|
|
US20050026957A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of treating nodulocystic acne
|
|
US20050026949A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoids without regard to body weight
|
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
|
JP2007518719A
(ja)
*
|
2003-12-26 |
2007-07-12 |
アラーガン インコーポレイテッド |
ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム
|
|
DE602005011928D1
(de)
|
2004-01-20 |
2009-02-05 |
Allergan Inc |
Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
|
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
|
WO2005110374A1
(en)
*
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
|
WO2006017347A2
(en)
*
|
2004-07-12 |
2006-02-16 |
Allergan, Inc. |
Opthalmic compositions and methods for treating ophthalmic conditions
|
|
EP1621191A1
(en)
*
|
2004-07-29 |
2006-02-01 |
Werner Bollag |
Treatment of inflammatory diseases by RXR Antagonists
|
|
WO2006030442A2
(en)
|
2004-09-16 |
2006-03-23 |
Gamida-Cell Ltd. |
Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
|
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
|
CN101316583A
(zh)
|
2005-09-30 |
2008-12-03 |
生命医药公司 |
用特异性rxr激动剂治疗癌症
|
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
|
TR201819157T4
(tr)
*
|
2006-05-16 |
2019-01-21 |
Io Therapeutics Llc |
Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
|
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
|
JP5699414B2
(ja)
*
|
2007-02-28 |
2015-04-08 |
ユニバーシティー オブ ケンタッキー リサーチ ファウンデイション |
レチノイン酸療法の効力を妨げることなくレチノイン酸療法の副作用を軽減する方法、および／又は、その効力を改善する方法
|
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
|
KR101041281B1
(ko)
*
|
2009-05-18 |
2011-06-14 |
주식회사 니프코코리아 |
자동차의 에어벤트 다이얼
|
|
DK2498783T3
(en)
|
2009-11-09 |
2018-12-10 |
Allergan Inc |
COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
|
|
TW201311295A
(zh)
|
2011-06-03 |
2013-03-16 |
Allergan Inc |
對皮脂腺之類視色素化合物之目標遞送
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
WO2013090616A1
(en)
|
2011-12-13 |
2013-06-20 |
Io Therapeutics, Inc. |
Autoimmune disorder treatment using rxr agonists
|
|
HK1202581A1
(en)
|
2012-02-13 |
2015-10-02 |
Gamida-Cell Ltd. |
Mesenchymal stem cells conditioned medium and methods of generating and using the same
|
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
|
US20140094512A1
(en)
|
2012-10-02 |
2014-04-03 |
Nikolas Gunkel |
Method of modulating the degree of adipose tissue deposited intramuscularly
|
|
EP2956096A1
(en)
|
2013-02-15 |
2015-12-23 |
Allergan, Inc. |
Sustained drug delivery implant
|
|
CN116077626A
(zh)
|
2015-10-31 |
2023-05-09 |
Io治疗公司 |
使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
|
|
EP3380086B1
(en)
|
2015-11-25 |
2021-10-13 |
IO Therapeutics, Inc. |
Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
|
|
JP2019509262A
(ja)
*
|
2016-02-03 |
2019-04-04 |
ガルデルマ・リサーチ・アンド・デヴェロップメント |
新規二芳香族プロピニル化合物、それらを含む薬学的および化粧用組成物ならびにそれらの使用
|
|
US10835507B2
(en)
|
2016-03-10 |
2020-11-17 |
Io Therapeutics, Inc. |
Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
|
|
KR102605349B1
(ko)
|
2016-03-10 |
2023-11-22 |
아이오 테라퓨틱스, 인크. |
Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
|
|
WO2017152725A1
(zh)
*
|
2016-03-11 |
2017-09-14 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
|
CN107176945B
(zh)
*
|
2016-03-11 |
2021-06-08 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
|
WO2017214575A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Io Therapeutics, Inc. |
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
|
|
WO2019014468A1
(en)
|
2017-07-13 |
2019-01-17 |
Io Therapeutics, Inc. |
RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY
|
|
US10363272B2
(en)
|
2017-08-31 |
2019-07-30 |
Io Therapeutics, Inc. |
RAR selective agonists in combination with immune modulators for cancer immunotherapy
|
|
CA3076373A1
(en)
|
2017-09-20 |
2019-03-28 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective rxr agonists
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
|
CA3242047A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist in treating drug resistant her2+ cancers
|
|
AU2022408160A1
(en)
|
2021-12-07 |
2024-06-06 |
Board Of Regents, The University Of Texas System |
Use of an rxr agonist and taxanes in treating her2+ cancers
|